Nuclear factor kappa B (NFB) is an important transcription factor that is involved in the response
Introduction
Type 1 diabetes mellitus (T1DM) is caused by the autoimmune destruction of the pancreatic beta (␤) cells in the islets of Langerhan. It is well known that genetic as well as environmental factors are implicated in the pathogenesis of this disease. The genes coding for certain major histocompatibility complex (MHC) HLA class II alleles are strongly associated with susceptibility to T1DM in Caucasoid populations. [1] [2] [3] The HLA susceptibility alleles make a major contribution to the genetic component of T1DM, however, non-HLA loci including insulin and certain cytokine genes may also play an important to this disease. [4] [5] [6] Nuclear factor kappa B (NFB) is a member of the relfamily proteins and is an eukaryotic transcription factor that is intricately involved in mediating the immune response. [7] [8] [9] [10] The gene coding for NFB is located on chromosome 4q24 and promotes the expression of over 150 target genes including those coding for cytokines such as tumour necrosis factor-␣, and interleukin-1␤; chemokines, adhesion molecules as well as increased expression of HLA molecules. It is also apparent that many viruses have NFB binding sites in their genome thereby inducing increased viral transcription by the cell's own defence system.
Inhibitor-B proteins (IB) inhibit NFB by trapping it in the cytoplasm. Phosphorylation of IB by kinases allows activation of the NFB, which translocates into the nucleus and binds DNA motifs. 8 Activation of NFB and subsequent release of cytokines occurs through a redoxsensitive mechanism 11, 12 and oxidative stress is the main inducer for activation of the pathway. NFB plays a role in protecting cells from apoptosis by upregulating the synthesis of anti-apoptotic gene products. 13 Long-term exposure to hyperglycaemia is an important risk factor for developing diabetic microvascular complications: neuropathy, nephropathy, and retinopathy. 14, 15 Several studies have demonstrated that chronic hyperglycaemia causes metabolic abnormalities such as oxidative stress, hypoxia, advanced glycated end products (AGEs) and changes in the NADH/NAD + ratio may contribute to the development of these complications. [16] [17] [18] The oxidative stress and AGEs produced by hyperglycaemia are an important source for free radical oxygen intermediates (ROIs); these free radicals are responsible for accelerating the vascular complications due to their inflammatory, necrotic and ischaemic effects. Recent studies have suggested that the increased activation of NFB is associated with the development of diabetic microvascular complications in those patients with either T1DM or T2D. [19] [20] [21] [22] It has previously been shown that increased activity of NFB is present in the peripheral blood mononuclear cells isolated from patients with diabetic nephropathy. 20 Hyperglycaemia has also been shown to activate NFB in porcine vascular smooth muscle cells. 21 These studies suggested that NFB might be involved in the pathogenesis of diabetic microvascular complication. The gene coding for aldose reductase (ALR2), the first and rate limiting of the polyol pathway has been also shown to have a NFB binding site. Recently, a polymorphic dinucleotide (CA) repeat has been identified in close proximity to the coding region of the human NFB gene 23 
Results
In our population, 18 alleles (A1-A18) of the (CA) repeat microsatellite in the regulatory region of the NFB gene were detected. The size of the alleles ranged from 120 to 154 base pairs (bp) (A1-A18) (Figure 1 ). The observed and expected frequency of the alleles was similar in both the patient and normal control populations and therefore conformed to the Hardy-Weinberg equation.
The frequency of the alleles in the patients and controls are shown in Table 1 . The A8 and A14 alleles were the most prevalent in the normal controls (19.8% and 28.4% respectively). In contrast, in patients with T1DM there was a highly significant decrease in the frequency of both the A8 as well as the A14 allele compared to the normal controls (6.2% vs 19.8%, 2 = 26.75, P Ͻ 0.0000002, Pc = 0.0000034 and 3.9% vs 28.4%, 2 = 79.80 P Ͻ 0.000001, Pc = 0.000017 respectively). In patients with T1DM, there was a highly significant increase in the frequency of the A10 (138 bp) allele compared with the normal controls (17.5% vs 2.7% respectively, 2 = 32.8, P Ͻ 0.000001, odds ratio =9.4).
More than 70 genotypes were identified in our population. Table 2 shows the frequency of the common genotypes. In the normal control population, the most common genotype was A8/A14 but this was only found in one of the 217 patients with T1DM (12.6% vs 0.5%, 2 = 22.1, P Ͻ 0.000002, Pc = 0.00014). The second most prevalent genotype in the normal control group was A14/A14 and this was completely absent from the patient group (9.9% vs 0.0% 2 = 19.3, P Ͻ 0.00001, Pc = 0.00007). Similarly, the A8/A11 genotype was found in 6.3% of the normal controls but was absent from the patient population ( 2 = 11.1, P Ͻ 0.0008). However, this difference was not Genes and Immunity Note: Allele frequencies are expressed as percentage of the total number of chromosomes. The numbers in parentheses is the number of chromosomes. *A8 P Ͻ 0.0000002, Pc Ͻ 0.000003 in the normal controls vs patients subgroups. **A10 P Ͻ 0.00000 in the patients subgroups vs normal controls. ***A14 P Ͻ 0.000001, Pc = 0.000017 in normal controls vs subgroups of type 1 diabetes. 
The table shows the frequency of genotypes with prevalence Ͻ3%. X = all other genotypes. *The A10/A11 genotype is the most common in patients with type 1 diabetes. **The A14/A14 genotype is prevalent with the normal controls.
significant after correction of the P-value (Pc = 0.06). In the patient group, the A9/A10 genotype was the most common genotype and was present in four of the 111 normal control subjects (12.0% vs 3.6%, 2 = 5.2, P Ͻ 0.02, Pc = NS). The A10/A11 genotype was found in 9.2% of the patients but was absent from the normal control group 2 = 9.3, P Ͻ 0.002, Pc = NS). The patients were classified into three groups according to the age at onset (AAO) of type 1 diabetes: Ͻ10, 10-20, Ͼ20 years. Table 3 shows the frequency of the NFB genotypes with respect to age at onset of T1DM and gender. The patients were categorised into Ͻ10, 10-20 or Ͼ20 years age at onset of diabetes. There were no significant differences in the frequency of the genotypes with age at onset although the A9/A10 genotype was found in only 4.8% of those diagnosed before the age of 10 years compared to 13.2% and 14.0% in the 10 to 20-year and Ͼ20-year age at onset respectively. There were no significant differences in the frequency of the NFB genotypes with gender. Table 4 shows the frequency of the common NFB alleles with respect to the presence or absence of diabetic microvascular disease after 20 years duration of diabetes. Whilst A9 was more common in those with either diabetic microvascular disease compared to those with no complications after 20 years of diabetes, these differences were not significant. All the other frequencies of the alleles were similar between the patient subgroups. 
DC, those patients with no nephropathy, retinopathy or overt neuropathy after 20 years duration of diabetes; DN, those patients with nephropathy; DNU, those patients with overt neuropathy; DR, those patients with retinopathy. There were no significant differences in the frequency of the NFB alleles between any of the patient groups.
Discussion
To our knowledge, this is the first study of NFB polymorphisms in either an autoimmune or inflammatory disease. The results suggest that the A10 allele may contribute to the susceptibility of T1DM whilst those individuals with the A14 allele have a reduced risk of developing T1DM. This polymorphism is located in close proximity to the coding region of the NFB gene. It has previously been shown that polymorphisms in the noncoding regions of cytokine genes can influence expression 24, 25 whilst enhancer elements up to 50 kb from the coding region can directly effect expression of transcription factors. 26 Consequently, the results described here could be attributed to differences in the expression of the NFB gene. At the present time, nothing is known about the influence of this microsatellite on the expression of the NFB gene, or regulatory sequences that may be located nearby. This may determine the direction and magnitude of the response of a cell to an external stress and whether it is channelled towards either apoptosis or, inflammation and necrosis. There is currently very little information on the mechanisms of islet ␤-cell death during the pre-diabetic period in man. It is possible that the A10 allele is associated with proinflammatory and anti-apoptotic responses whilst conversely, the A14 allele is anti-inflammatory and proapoptotic. This might be related to variable amounts of NFB protein. In the case of the anti-apoptotic response, too much protection of the cell perhaps because of its increased abundance would prevent apoptosis but would cause increased necrosis. This would have a detrimental effect by allowing intracellular proteins and other molecules to be exposed to the immune system thereby provoking the autoimmune response.
Recent studies have shown that increased activation of NFB is significantly increased in patients with either T1DM or, T2D and micro vascular disease. [19] [20] [21] [22] In this study we have found no association with the NFB allele or genotypes with either the presence or absence of diabetic microvascular complications in those patients with T1DM. It is possible that an association may exist with microvascular disease in those patients with T2DM. There is no information at the present time on the functional role of the A10, A14 or other polymorphisms in the regulatory region of this gene. It is possible that these polymorphisms may be related to function perhaps by altering the efficiency of its transcription under different types of stress. Activation of NFB occurs at the protein rather than the genetic level although prolonged chronic exposure to stress such as hyperglycaemia would lead to increase abundance of the transcription factor within the cell. IB may also play an important role in enabling the translocation of the transcription factor to the nucleus.
In conclusion, we have a strong association between a polymorphism in close proximity to the NFB gene and susceptibility to T1DM but not with the long-term micro vascular complications of this disease. Previous studies have found no evidence for linkage of 4q24 with susceptibility to T1DM. However, these genome screens used highly selective multiplex families whilst in this study the majority of cases are sporadic cases. Further, the multiplex family studies were not always able to replicate the association of non-MHC genes with susceptibility to T1DM across or even within similar populations. It remains a possibility that the polymorphism is related to the presence or absence of microvascular complications rather than diabetes itself. Further studies are now required to determine whether there is any relationship between the NFB alleles and function.
Materials and methods

Subjects
Two hundred and seventeen British Caucasoid patients with T1DM with or without complications and 111 normal healthy controls (NC) were studied. All the patients had attended the Diabetic Clinic, Derriford Hospital, Plymouth, UK. The patients were classified according to their microvascular complications as follows:
Uncomplicated diabetic controls (DC n = 38): these patients have had T1DM for at least 20 years but remain free of retinopathy, microalbuminuria (defined by the Diabetes Control and Complications Trial as 15-30 mg/l), proteinuria, and overt neuropathy.
Nephropathy patients (DN n = 48): these patients have had T1DM for at least 10 years with persistent proteinuria (urine Albustix positive on at least three consecutive occasions over 12 months or three successive total urinary albumin excretion (UAE) rates more than 0.5 g/24 h) in the absence of haematuria or infection on midstream urine samples. The presence of nephropathy was always associated diabetic retinopathy.
Retinopathy patients (DR n = 76): these patients had retinopathy defined as more than five dots or blots per eye, hard or soft exudates, new vessels or flourescein angiographic evidence of maculopathy or previous laser treatment for preproliferative or proliferative retinopathy and maculopathy or vitrous haemorrhage. None of these patients had microalbuminuria or protienuria.
Neuropathy patients (DNU n = 55): these patients had overt neuropathy defined as clinical evidence of peripheral or autonomic neuropathy. The criteria for inclusion in this category have previously been published. 27 Normal control samples were consisted of 80 cord bloods collected sequentially after normal obstetric delivery from the labour ward, Derriford Hospital. The remaining samples were obtained from normal healthy schoolchildren (n = 15) and adults (n = 16). The clinical characteristics of the patients and control populations are shown in Table 5 .
Genes and Immunity
Extraction of genomic DNA and analysis of the microsatellite polymorphism DNA was extracted from peripheral blood collected into EDTA-containing tubes using Nucleon II DNA extraction kit (Tepnel Life Science PLC, Manchester, UK) following the manufacturer's instructions. Briefly, the samples were lysed and deproteinised before extraction with chloroform. Finally, DNA was isolated by ethanol precipitation and dissolved in 500 l of double distilled water. The (CA)n region was amplified by polymerase chain reaction (PCR) using primers 23 (NF(B 1 1F) 5Ј-CTTCAG TATCTAAGAGTATCCT-3Ј (108 111 762 4q24 forward HGP-UCSC) and (NFB 1 1R) 5Ј-CAAGTAAGAC TCTACGGAGTC-3Ј (108 111 625 4q24 reverse HGP-UCSC). The forward primer was labelled with [ 32 P␥] dATP by T4 polynucleotide kinase (Amersham Pharmacia, UK Limited). Fifty to 100 ng of genomic DNA was used for amplification in a volume of 30 l with a hot start for 4 min at 94°C. Then 30 cycles were performed at 94°C for 30 sec, at 53.5°C for 2 min, at 72°C for 30 sec. The resulting fragments and a molecular weight ladder were electrophoresed through 6% denaturing polyacrylamide gels at 1800 W for 3 h. The dried gels were autoradiographed at −80°C for 18 h. The films were visualised for allelic and genotypic identifications.
Statistical analysis
The frequencies of alleles and genotypes were calculated by Statgraphics software (Statistical Graphics Corp, USA, 1996) . The comparison between patient's subgroups and control subjects was made by 2 × 2 contingency tables using the 2 test. The P values were corrected for the number of comparisons made (Pc) using the Bonferroni inequality method, 28 and Pc values of Ͻ0.05 were considered to be significant.
